Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Sci. Signal., 8 September 2009
Vol. 2, Issue 87, p. re6
[DOI: 10.1126/scisignal.287re6]
REVIEWS
Oncogenic EGFR Signaling Networks in Glioma
Paul H. Huang1*,
Alexander M. Xu2, and
Forest M. White2,3
1 Protein Networks Team, Section of Cell and Molecular Biology, Institute of Cancer Research, London SW3 6JB, UK. 2 Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. 3 Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Abstract:
The epidermal growth factor receptor (EGFR) is a primary contributor to glioblastoma (GBM) initiation and progression. Here, we examine how EGFR and key downstream signaling networks contribute to the hallmark characteristics of GBM such as rapid cancer cell proliferation and diffused invasion. Additionally, we discuss current therapeutic options for GBM patients and elaborate on the mechanisms through which EGFR promotes chemoresistance. We conclude by offering a perspective on how the potential of integrative systems biology may be harnessed to develop safe and effective treatment strategies for this disease.
The editors suggest the following Related Resources on Science sites:
In Science Signaling
EDITORS' CHOICE
Nancy R. Gough (12 July 2011) Sci. Signal.4 (181), ec191.
[DOI: 10.1126/scisignal.4181ec191] |Abstract »
EDITORIAL GUIDES
Elizabeth M. Adler and Nancy R. Gough (29 March 2011) Sci. Signal.4 (166), eg3.
[DOI: 10.1126/scisignal.2002014] |Abstract »|Full Text »|PDF »
EDITORS' CHOICE
Elizabeth M. Adler (25 January 2011) Sci. Signal.4 (157), ec24.
[DOI: 10.1126/scisignal.4157ec24] |Abstract »
RESEARCH ARTICLES
Qi-Wen Fan, Christine Cheng, Chris Hackett, Morri Feldman, Benjamin T. Houseman, Theodore Nicolaides, Daphne Haas-Kogan, C. David James, Scott A. Oakes, Jayanta Debnath, Kevan M. Shokat, and William A. Weiss (9 November 2010) Sci. Signal.3 (147), ra81.
[DOI: 10.1126/scisignal.2001017] |Editor's Summary »|Abstract »|Full Text »|PDF »|Supplementary Materials »
EDITORIAL GUIDES
Elizabeth M. Adler (9 November 2010) Sci. Signal.3 (147), eg11.
[DOI: 10.1126/scisignal.3147eg11] |Abstract »|Full Text »|PDF »
RESEARCH ARTICLES
Erik Slinger, David Maussang, Andreas Schreiber, Marco Siderius, Afsar Rahbar, Alberto Fraile-Ramos, Sergio A. Lira, Cecilia Söderberg-Nauclér, and Martine J. Smit (3 August 2010) Sci. Signal.3 (133), ra58.
[DOI: 10.1126/scisignal.2001180] |Editor's Summary »|Abstract »|Full Text »|PDF »|Supplementary Materials »
RESEARCH ARTICLES
Deliang Guo, Robert M. Prins, Julie Dang, Daisuke Kuga, Akio Iwanami, Horacio Soto, Kelly Y. Lin, Tiffany T. Huang, David Akhavan, M. Benjamin Hock, Shaojun Zhu, Ava A. Kofman, Steve J. Bensinger, William H. Yong, Harry V. Vinters, Steve Horvath, Andrew D. Watson, John G. Kuhn, H. Ian Robins, Minesh P. Mehta, Patrick Y. Wen, Lisa M. DeAngelis, Michael D. Prados, Ingo K. Mellinghoff, Timothy F. Cloughesy, and Paul S. Mischel (15 December 2009) Sci. Signal.2 (101), ra82.
[DOI: 10.1126/scisignal.2000446] |Editor's Summary »|Abstract »|Full Text »|PDF »|Supplementary Materials »
EDITORS' CHOICE
Nancy R. Gough (15 September 2009) Sci. Signal.2 (88), ec304.
[DOI: 10.1126/scisignal.288ec304] |Abstract »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Chronic Activation of Wild-Type Epidermal Growth Factor Receptor and Loss of Cdkn2a Cause Mouse Glioblastoma Formation.
J. Acquaviva, H. J. Jun, J. Lessard, R. Ruiz, H. Zhu, M. Donovan, S. Woolfenden, A. Boskovitz, A. Raval, R. T. Bronson, et al. (2011)
Cancer Res.
71, 7198-7206
|Abstract »|Full Text »|PDF »
Therapeutic Potential of AZD1480 for the Treatment of Human Glioblastoma.
B. C. McFarland, J.-Y. Ma, C. P. Langford, G. Y. Gillespie, H. Yu, Y. Zheng, S. E. Nozell, D. Huszar, and E. N. Benveniste (2011)
Mol. Cancer Ther.
10, 2384-2393
|Abstract »|Full Text »|PDF »
M. Sanson, F. J. Hosking, S. Shete, D. Zelenika, S. E. Dobbins, Y. Ma, V. Enciso-Mora, A. Idbaih, J.-Y. Delattre, K. Hoang-Xuan, et al. (2011)
Hum. Mol. Genet.
20, 2897-2904
|Abstract »|Full Text »|PDF »
Pnck induces ligand-independent EGFR degradation by probable perturbation of the Hsp90 chaperone complex.
T. B. Deb, A. H. Zuo, Y. Wang, R. J. Barndt, A. K. Cheema, S. Sengupta, C. M. Coticchia, and M. D. Johnson (2011)
Am J Physiol Cell Physiol
300, C1139-C1154
|Abstract »|Full Text »|PDF »
Setting the Standards for Signal Transduction Research.
J. Saez-Rodriguez, L. G. Alexopoulos, and G. Stolovitzky (2011)
Science Signaling
4, pe10
|Abstract »|Full Text »|PDF »
Sequential Multiplex Analyte Capturing for Phosphoprotein Profiling.
O. Poetz, T. Henzler, M. Hartmann, C. Kazmaier, M. F. Templin, T. Herget, and T. O. Joos (2010)
Mol. Cell. Proteomics
9, 2474-2481
|Abstract »|Full Text »|PDF »
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.
M.-d.-M. Inda, R. Bonavia, A. Mukasa, Y. Narita, D. W. Y. Sah, S. Vandenberg, C. Brennan, T. G. Johns, R. Bachoo, P. Hadwiger, et al. (2010)
Genes & Dev.
24, 1731-1745
|Abstract »|Full Text »|PDF »
Mig-6 controls EGFR trafficking and suppresses gliomagenesis.
H. Ying, H. Zheng, K. Scott, R. Wiedemeyer, H. Yan, C. Lim, J. Huang, S. Dhakal, E. Ivanova, Y. Xiao, et al. (2010)
PNAS
107, 6912-6917
|Abstract »|Full Text »|PDF »
